STOCK TITAN

Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Positive
  • None.
Negative
  • None.

GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually. Members of management are scheduled to present on Wednesday, March 13, 2024, at 2:40 pm ET.

A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: investors.hyperfine.io. The webcasts will be archived and available for replay for at least 90 days after the event.

For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Investor Contact

Marissa Bych

Gilmartin Group LLC

marissa@gilmartinir.com

Source: Hyperfine, Inc.

FAQ

When will Hyperfine, Inc. present at the Oppenheimer Healthcare MedTech & Services Conference?

Hyperfine, Inc. will present at the Oppenheimer Healthcare MedTech & Services Conference on Wednesday, March 13, 2024, at 2:40 pm ET.

What is the name of Hyperfine, Inc.'s portable MR brain imaging system?

Hyperfine, Inc.'s portable MR brain imaging system is called the Swoop® system.

Where can investors watch the live webcast of Hyperfine, Inc.'s presentation?

Investors can watch the live webcast of Hyperfine, Inc.'s presentation on the 'Investors' section of the company's website at investors.hyperfine.io.

Hyperfine, Inc.

NASDAQ:HYPR

HYPR Rankings

HYPR Latest News

HYPR Stock Data

66.75M
52.43M
9.5%
24.35%
2.14%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GUILFORD